Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
This article was originally published in The Pink Sheet Daily
The company plans to launch six to seven new products by the end of the year, and 10 additional products in 2010.
You may also be interested in...
As Regulatory Pathways Are Debated, Tidal Wave Of Biosimilars Can Create A $10 Billion Opportunity By 2015; Indian Companies Aim For Big Gains
MUMBAI - Patent expiries on biotech-based drugs starting in 2012 accompanied with a clearer regulatory framework will throw open a $10 billion market opportunity for biosimilars in the U.S. and Europe; Indian companies including Dr. Reddy's, Intas, Wockhardt and Ranbaxy are all bolstering their product pipelines to prepare for those markets
MUMBAI - India's top generic drug maker, Cipla, is speeding up its entry into biosimilars with the newly named Biomab, an equal stake joint venture with an undisclosed Chinese company
BEIJING - Flush with cash from expanding earnings, leading Chinese biotech outfit 3SBio is scanning the globe for promising in-licensing deals to complement its in-house drug development pipeline and is exploring the potential to one day enter the biosimilars markets in the United States and the European Union